Spyre Therapeutics presents new clinical and preclinical data for SPY001 002 003 at UEGW2026

Spyre Therapeutics presents new clinical and preclinical data for SPY001 002 003 at UEGW2026
Spyre Therapeutics reveals IBD data

Spyre Therapeutics announced the presentation of clinical data across its SPY001, SPY002, and SPY003 programs as well as new preclinical findings at UEGW2026.

The company stated that these results demonstrate additive efficacy, supporting its approach to investigating combination therapies for inflammatory bowel disease. Spyre Therapeutics is focused on developing novel treatments for IBD using multi-drug strategies.

Spyre Therapeutics recently secured $350 million to support late-stage development of its SPY072 program, bringing its total capital raised to over $2 billion. The company’s latest fundraising round was reported in a prior filing. This funding positions Spyre to advance its multi-drug strategies for inflammatory bowel disease.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.